ChemicalBook CAS DataBase List 385425-03-6

385425-03-6

Name	[3-(4-methylphenyl)-5-[(E)-morpholin-4-ylmethylideneamino]imidazol-4-yl]-phenylmethanone
CAS	385425-03-6
Molecular Formula	C22H22N4O2
MDL Number	MFCD01551710
Molecular Weight	374.44
MOL File	385425-03-6.mol

Chemical Properties

Boiling point	618.3±65.0 °C(Predicted)
density	1.22±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	DMSO : 50 mg/mL (133.53 mM; Need ultrasonic)
form	Solid
pka	3.47±0.20(Predicted)
color	Light yellow to yellow
InChI	1S/C22H22N4O2/c1-17-7-9-19(10-8-17)26-16-24-22(23-15-25-11-13-28-14-12-25)20(26)21(27)18-5-3-2-4-6-18/h2-10,15-16H,11-14H2,1H3
InChIKey	UCDKLMTYEDPEMY-UHFFFAOYSA-N
SMILES	CC1=CC=C(C=C1)N2C=NC(=C2C(=O)C3=CC=CC=C3)N=CN4CCOCC4

Safety Data

WGK Germany	WGK 3
Storage Class	11 - Combustible Solids

Hazard Information

Uses

IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model[1][2].

Biological Activity

Cell permeable: yes''Reversible: yes

in vivo

IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles^[1].
IBS008738 (30 μM, 100 μL) prevents Dexamethasone (HY-14648)-induced muscle atrophy^[1].
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI)^[2].

Animal Model:	Six-week-old female BALB/cByJ mice^[1]
Dosage:	3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS)
Administration:	Injected into the tibialis anterior (TA) muscle of mice under anesthesia.
Result:	Facilitated muscle repair in Cardiotoxin-injected muscles.

Animal Model:	Six-week-old female BALB/cByJ mice^[1]
Dosage:	30 μM (100 μL)
Administration:	Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13.
Result:	Prevented Dexamethasone-induced muscle atrophy.

References

[1] Yang Z, et al. Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol. 2014;34(9):1607-1621. DOI:10.1128/MCB.01346-13
[2] Zou R, et al. TAZ Activator Is Involved in IL-10-Mediated Muscle Responses in an Animal Model of Traumatic Brain Injury. Inflammation. 2017;40(1):100-105. DOI:10.1007/s10753-016-0457-5

Supplier

Send Inquriy